Fullerton Fund Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-12,607
Closed -$726K – 124
2026
Q2
$726K Buy
12,607
+2,538
+25% +$146K 0.05% 50
2026
Q1
$611K Buy
+10,069
New +$587K 0.05% 55
2025
Q3
– Sell
-3,547
Closed -$164K – 100
2025
Q2
$164K Sell
3,547
-4,750
-57% -$233K 0.01% 93
2025
Q1
$506K Buy
+8,297
New +$484K 0.03% 82
2024
Q2
– Sell
-9,408
Closed -$510K – 139
2024
Q1
$510K Buy
+9,408
New +$479K 0.02% 71
2021
Q3
– Sell
-3,538
Closed -$236K – 69
2021
Q2
$236K Buy
+3,538
New +$231K 0.02% 76
2020
Q4
– Sell
-3,180
Closed -$192K – 81
2020
Q3
$192K Buy
+3,180
New +$191K 0.03% 58

Other funds holding BMY

Fullerton Fund Management's BMY Position: Q3 2026 in Review

Fullerton Fund Management sold out of Bristol-Myers Squibb (BMY) in Q3 2026, closing a stake of 12,607 shares — an estimated $726K sold.

Fullerton Fund Management first reported a position in BMY in Q3 2020 and held it in 7 quarters. The position peaked at $726K in Q2 2026. 2,569 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Fullerton Fund Management reported no remaining Bristol-Myers Squibb position as of Q3 2026 after selling out during the quarter.
  • Fullerton Fund Management sold 12,607 Bristol-Myers Squibb shares in Q3 2026, an estimated $726K.
  • Fullerton Fund Management first reported a position in Bristol-Myers Squibb in Q3 2020 and held it in 7 quarters.
  • Fullerton Fund Management's Bristol-Myers Squibb position peaked at $726K in Q2 2026.
  • 2,569 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Fullerton Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.